Holen Sie sich die Stockscreener-App
499.56
0.48%
1.59
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt UTHR?
Forum
Prognose
Aktiensplit
United Therapeutics Corp Aktie (UTHR) Neueste Nachrichten
United Therapeutics Launches $477.6M Accelerated Share Buyback - Minichart
United Therapeutics Launches $477.6 Million Accelerated Share Repurchase With Citi - TradingView
United Therapeutics (UTHR) moves to return $4B to shareholders with new buyback - Stock Titan
United Therapeutics (UTHR) CEO sells 9,500 shares under preset trading plan - Stock Titan
United Therapeutics Corporation at Wells Fargo Healthcare Conference Transcript - GuruFocus
United Therapeutics Corporation Announces Accelerated Share Repurchase Agreement for Remainder of $2.0 Billion Authorization - marketscreener.com
United Therapeutics Corporation (UTHR) Stock Analysis: Insights on a 36.24% Potential Upside - DirectorsTalk Interviews
United Therapeutics (NASDAQ: UTHR) CEO sells 9,500 shares under 10b5-1 plan - Stock Titan
MannKind Stock Plummets After Partner United Therapeutics Unveils New ‘Category Killer Product’ - Stocktwits
United Therapeutics (UTHR) Down 8% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Anheuser-Busch plant in Merrimack sold to United Therapeutics for $47.5M - UnionLeader.com
United Therapeutics EVP Paul A. Mahon Executes Stock Option Exercise and Sells Shares Under 10b5-1 Plan - kalkinemedia.com
United Therapeutics (UTHR) counsel sells 8,300 shares under preset plan - Stock Titan
United Therapeutics (UTHR) CEO offloads 9,500 shares in planned trade - Stock Titan
United Therapeutics (NASDAQ:UTHR) Offers Growth At A Fair Price - Kalkine Media
United Therapeutics (NASDAQ:UTHR) Fits the Growth-at-a-Reasonable-Price Model - ChartMill
Merrimack’s Anheuser-Busch property sold for $47m - The Cabinet Press
United Therapeutics Corp (UTHR) Stock Down 4.1% but Still Overva - GuruFocus
United Therapeutics (UTHR) CEO sells 9,500 shares under trading plan - Stock Titan
United Therapeutics Slides as Investors Weigh Insider Selling Against a New Regulatory Milestone - Quiver Quantitative
United Therapeutics FDA Accepts Tyvaso IPF Filing | UTHR Stock News - Stock Titan
United Therapeutics (UTHR) CEO sells more shares under preset trading plan - Stock Titan
Stewartville's xenotransplant pig facility is ready for animals - Post Bulletin
Four healthcare conferences will host United Therapeutics executives in September. The talks will be streamed live. - Stock Titan
United Therapeutics (UTHR) CEO sells 9,500 shares under preset plan - Stock Titan
United Therapeutics Corporation (UTHR) Stock Analysis: Evaluating a 28.88% Upside Potential in the Healthcare Sector - DirectorsTalk Interviews
United Therapeutics (UTHR) CEO sells shares via preset options plan - Stock Titan
United Therapeutics to present drug trial data at conferences - Investing.com
United Therapeutics will present data showing improved lung function in idiopathic pulmonary fibrosis - Stock Titan
United Therapeutics (UTHR) CEO exercises options, sells 9,500 shares - Stock Titan
United Therapeutics (UTHR) CEO sells 9,500 shares under 10b5-1 plan - Stock Titan
United Therapeutics (NASDAQ: UTHR) CEO sells 9,500 shares in preset plan - Stock Titan
United Therapeutics (NASDAQ: UTHR) CEO sells 9,500 under 10b5-1 plan - Stock Titan
FDA accepts United Therapeutics’ ralinepag application for PAH - Investing.com
United Therapeutics (NASDAQ: UTHR) CEO sale part of 1,734,410-option 10b5-1 plan - Stock Titan
United Therapeutics (UTHR) legal chief sells 8,300 shares - Stock Titan
United Therapeutics (NASDAQ: UTHR) CEO trades under 1,734,410-option 10b5-1 plan - Stock Titan
United Therapeutics (NASDAQ:UTHR) Stands Out as a Quality Stock with Durable Profitability and Strong Returns - ChartMill
ETFs Investing in United Therapeutics Corporation Stocks - TradingView
United Therapeutics (UTHR) CEO sells shares under preset trading plan - Stock Titan
United Therapeutics (NASDAQ: UTHR) CEO sells 9,500 shares - Stock Titan
United Therapeutics (UTHR) Q2 2026 Earnings Call Transcript - AOL.com
United Therapeutics Completes Enrollment in Phase 3 PPF Trial of Tyvaso - marketscreener.com
United Therapeutics completes enrollment in lung fibrosis trial - Investing.com
United Therapeutics Corporation Announces Full Enrollment of the TETON-PPF Study of Inhaled Treprostinil for the Treatment of Progressive Pulmonary Fibrosis - marketscreener.com
United Therapeutics Corporation Completes Enrollment Of TETON-PPF Study Of Inhaled Treprostinil For Progressive Pulmonary Fibrosis - marketscreener.com
United Therapeutics Corporation (UTHR) Stock Analysis: Potential 30% Upside Captivates Investors - DirectorsTalk Interviews
Mid Cap Index Fund's United Therapeutics Corp(UTHR) Holding History - GuruFocus
United Therapeutics CEO Martine Rothblatt sells $4.79m in stock - Investing.com
United Therapeutics CEO Martine Rothblatt sells $4.79m in stock By Investing.com - Investing.com South Africa
United Therapeutics (UTHR) CEO Rothblatt exercises 9,500 options and sells 9,500 shares via 10b5-1 plan - Stock Titan
United Therapeutics’s Q2 Earnings Call: Our Top 5 Analyst Questions - Yahoo Finance
United Therapeutics CEO Rothblatt sells $4.89m in stock By Investing.com - Investing.com Nigeria
United Therapeutics CEO Rothblatt sells $4.89m in stock - Investing.com
Martine Rothblatt Sells 9,500 Shares of United Therapeutics (NASDAQ:UTHR) Stock - MarketBeat
United Therapeutics Corp (UTHR) CEO’s trust sells 9,500 shares under 10b5-1 plan - Stock Titan
United Therapeutics (UTHR) Stock Looks Undervalued Despite Fresh NDA Filings - simplywall.st
United Therapeutics (NASDAQ:UTHR): A Peter Lynch-Style GARP Play - ChartMill
0.54%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):